Giloz 250mg Capsule

Giloz 250mg Capsule is an anticancer medicine with Temozolomide as an active ingredient. It prescribes to treat specific type of cancer of the brain and other conditions, as determined by the doctor. It is also used to treat brain tumors if they return or get worse after standard treatment. It should be taken in dose and duration as advice by the doctor. Don't take more than the recommended dose.

• Brain tumor

Giloz 250mg Capsule may cause some side effects that vary from one patient to another. Most side effects do not require any medical attention and disappear as your body adjusts to the medicine.

Common side effects include:

• Nausea
• Vomiting
• Constipation
• Headache
• Fatigue
• Convulsion
• Coordination disorder
• Diarrhea
• Dizziness
• Fever
• Hair loss
• Hemiparesis (weakness on one side of the body)
• Insomnia (difficulty sleeping)
• Loss of appetite
• Memory loss
• Rash
• Viral infection
• Weakness

Contact your healthcare provider if you face any unusual or persistent side effects.

• Take Giloz 250mg Capsule as prescribed by your doctor. Do not crush or break the tablet. Take this medicine on an empty stomach one hour before or two hours after meals.
• In case of an overdose, the doctor will provide emergency medical treatment. Do not stop or change the dose without informing your doctor.
  
  

Glioz 250mg Capsule is an anti-cancer medication. It contains Temozolomide that works by entering the brain tissues and works by damaging the genetic material (DNA and RNA) of the cancer cells to inhibit their growth. Thereby, stop the growth and multiplication of cancer cells.

• Mutter, N., & Stupp, R. (2006). Temozolomide: a milestone in neuro-oncology and beyond? Expert review of anticancer therapy, 6(8), 1187-1204. https://pubmed.ncbi.nlm.nih.gov/16925485/
• Lee, S. Y. (2016). Temozolomide resistance in glioblastoma multiforme. Genes & diseases, 3(3), 198-210. https://pubmed.ncbi.nlm.nih.gov/30258889/
• Stupp, R., Gander, M., Leyvraz, S., & Newlands, E. (2001). Current and future developments in the use of temozolomide for the treatment of brain tumours. The lancet oncology, 2(9), 552-560. https://pubmed.ncbi.nlm.nih.gov/11905710/
• Zhang, J., FG Stevens, M., & D Bradshaw, T. (2012). Temozolomide: mechanisms of action, repair and resistance. Current molecular pharmacology, 5(1), 102-114. https://pubmed.ncbi.nlm.nih.gov/22122467/
• Friedman, H. S., Kerby, T., & Calvert, H. (2000). Temozolomide and treatment of malignant glioma. Clinical cancer research, 6(7), 2585-2597. https://pubmed.ncbi.nlm.nih.gov/10914698/